• Je něco špatně v tomto záznamu ?

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

MD. Snape, M. Voysey, A. Finn, G. Bona, S. Esposito, N. Principi, J. Diez-Domingo, E. Sokal, D. Kieninger, R. Prymula, PM. Dull, I. Kohl, M. Barone, H. Wang, D. Toneatto, AJ. Pollard, . ,

. 2016 ; 35 (4) : e113-23.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000661

BACKGROUND: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. METHODS: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naïve "Control" participants aged 12, 18 or 24 months received 2 doses of 4CMenB 2 months apart. RESULTS: One thousand five hundred eighty-eight participants were recruited. At 12 months, before any booster doses, the proportions with hSBA titers ≥1:5 for strain 44/76-SL (testing vaccine component fHBP) were 73% (120/165) for the "246Con" group, 85% (125/147) for "246Int," 57% (51/90) for "234Con" and 13% (26/199) for Controls. For strain 5/99 (NadA) proportions were ≥96% (all 4CMenB-recipients) and 1% (Controls). For strain NZ98/254 (PorA), these were 18-35% (4CMenB-recipients) and 1% (Controls). By 24 months, 4CMenB-recipient proportions were 13-22% (44/76-SL), 82-94% (5/99) and 7-13% (NZ98/254) and in controls ≤4%. After a 12-month booster-dose, ≥95% of previously immunized participants had titers ≥1:5 (all strains). CONCLUSIONS: A 4CMenB booster-dose can overcome waning hSBA titers after early-infant immunization. Administration at 12 months could help to maintain immunity during an age of high risk, and the persistence of this response requires further study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000661
003      
CZ-PrNML
005      
20170119105614.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/INF.0000000000001056 $2 doi
024    7_
$a 10.1097/INF.0000000000001056 $2 doi
035    __
$a (PubMed)26756390
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Snape, Matthew D $u From the *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; †NIHR Oxford Biomedical Centre, Oxford University Hospital NHS Trust, Oxford, United Kingdom; ‡Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; §Bristol Children's Vaccine Centre, University of Bristol and University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom; ¶Azienda Ospedaliero-Universitaria, Azienda Ospedaliero-Universitaria Maggiore della Carità-Clinica Pediatrica, Novara, Italy; ‖Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; **Vaccine Research Department, FISABIO-Public Health, Valencia, Spain; ††Department of Pediatrics, Cliniques Saint Luc, Université Catholique de Louvain, Bruxelles, Belgium; ‡‡Clinical Trial Centre, Department of Pediatrics, Johannes Gutenberg University Medical School, Mainz, Germany; §§Department of Social Medicine, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic; ¶¶Novartis Vaccines and Diagnostics Inc., Cambridge, MA; ‖‖Novartis Vaccines and Diagnostics S.r.l., Siena, Italy; and ***Novartis Pharma BV, Amsterdam, The Netherlands.
245    10
$a Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age / $c MD. Snape, M. Voysey, A. Finn, G. Bona, S. Esposito, N. Principi, J. Diez-Domingo, E. Sokal, D. Kieninger, R. Prymula, PM. Dull, I. Kohl, M. Barone, H. Wang, D. Toneatto, AJ. Pollard, . ,
520    9_
$a BACKGROUND: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. METHODS: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naïve "Control" participants aged 12, 18 or 24 months received 2 doses of 4CMenB 2 months apart. RESULTS: One thousand five hundred eighty-eight participants were recruited. At 12 months, before any booster doses, the proportions with hSBA titers ≥1:5 for strain 44/76-SL (testing vaccine component fHBP) were 73% (120/165) for the "246Con" group, 85% (125/147) for "246Int," 57% (51/90) for "234Con" and 13% (26/199) for Controls. For strain 5/99 (NadA) proportions were ≥96% (all 4CMenB-recipients) and 1% (Controls). For strain NZ98/254 (PorA), these were 18-35% (4CMenB-recipients) and 1% (Controls). By 24 months, 4CMenB-recipient proportions were 13-22% (44/76-SL), 82-94% (5/99) and 7-13% (NZ98/254) and in controls ≤4%. After a 12-month booster-dose, ≥95% of previously immunized participants had titers ≥1:5 (all strains). CONCLUSIONS: A 4CMenB booster-dose can overcome waning hSBA titers after early-infant immunization. Administration at 12 months could help to maintain immunity during an age of high risk, and the persistence of this response requires further study.
650    _2
$a protilátky bakteriální $x krev $x imunologie $7 D000907
650    _2
$a předškolní dítě $7 D002675
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a očkovací schéma $7 D007115
650    12
$a sekundární imunizace $7 D007117
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meningokoková meningitida $x prevence a kontrola $7 D008585
650    _2
$a meningokokové vakcíny $x aplikace a dávkování $x škodlivé účinky $x imunologie $7 D022401
650    _2
$a Neisseria meningitidis séroskupiny B $x imunologie $7 D038541
650    _2
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a vakcinace $7 D014611
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Voysey, Merryn
700    1_
$a Finn, Adam
700    1_
$a Bona, Gianni
700    1_
$a Esposito, Susanna
700    1_
$a Principi, Nicola
700    1_
$a Diez-Domingo, Javier
700    1_
$a Sokal, Etienne
700    1_
$a Kieninger, Dorothee
700    1_
$a Prymula, Roman
700    1_
$a Dull, Peter M
700    1_
$a Kohl, Igor
700    1_
$a Barone, Michelangelo
700    1_
$a Wang, Huajun
700    1_
$a Toneatto, Daniela
700    1_
$a Pollard, Andrew J
700    1_
$a ,
773    0_
$w MED00003732 $t The Pediatric infectious disease journal $x 1532-0987 $g Roč. 35, č. 4 (2016), s. e113-23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26756390 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170119105723 $b ABA008
999    __
$a ok $b bmc $g 1179801 $s 961228
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 35 $c 4 $d e113-23 $i 1532-0987 $m The Pediatric infectious disease journal $n Pediatr Infect Dis J $x MED00003732
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace